Clinical Trial Search

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Percent Change of Headache Days Compared to Baseline — -13.50; -36.50 percent change of headache days

Primary: Total Number of Responders — 17 Participants

Primary: Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline — 4.4; 4.7 Moderate to severe headache days…

Primary: Migraine Frequency at 12 Weeks — -5.5; -3.9 days

Primary: Number of Participants With Any Treatment Emergent Adverse Events (TEAEs) — 91 Participants

Primary: Percent Change of Migraine Headache Days Compared to Baseline — -8.06; -56.37 percent migraine headache days per month

Primary: Numeric Rating Scale (NRS) — 3.18; 3.78; 2.53; 3.51 units on a scale

Primary: Adverse Events (First 12 Weeks) — 17; 27; 5; 1 events

Primary: Change From Baseline in Mean Monthly Hours of at Least Moderate Headache Pain Intensity Over Months 1, 2, and 3 — -23.38; -31.33 hours/month — p=< 0.001

Primary: Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment — 495; 400; 67; 46 Number of attacks

Primary: Frequency of Moderate to Severe Headache Days — 9.3; 9.1 days

Primary: Migraine Headache Index (MHI) at 1 Year — 7.81; 3.73 index score

Primary: Proportion of Patients With Treatment Discontinuation Due to an Adverse Event (AE) During the Double-blind Treatment Epoch/Period (DBTE) — 41; 151 Participants — p=<.001

Primary: Visual Analog Scale — 8.3; 8.4; 5.3; 5.3 units on a scale

Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days

Primary: 75% Migraine Responder Rate — 38; 37; 33; 33 Participants — p=0.0330

Primary: Mean Change From Baseline in the Monthly (28 Day) Average Number of Headache Days of at Least Moderate Severity During the 12-week Period After the First Dose of…

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027

Primary: Change From Baseline in Monthly Migraine Days — -8.2; -7.7; -5.6 Migraine Days — p=<0.0001

Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants

Primary: Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7. — -7.61; -6.67; -9.72; -5.22 days

Primary: DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -0.6; -3.7; -4.1 days/month…

Primary: Change From Baseline in the Frequency of Headache Days — 22.0; -10.7 headache days

Primary: Number of Adverse Events — 1 Participants

Primary: Change in Headache Relief — 23 percentage of headaches resolved — p=.079

Primary: Visual Analog Scale — 8.1; 7.9; 7.9; 5.9 score on a scale